Medical imaging spin-off RAYDIAX has secured €7.5 million to take its therapy-assistance CT scanner “TACT” into first-in-human studies and toward market launch. The financing combines €5 million in venture capital from existing business angels, current investor bmp Ventures with the IBG funds, and the newly participating GETEC Family Office of Dr. Karl Gerhold.
Alongside the equity round, the company has been awarded €2.5 million from the European Commission EIC Accelerator, one of Europe’s most selective deep-tech support mechanisms.
Preparing for first-in-human studies
The newly raised capital will drive three priority areas. First, RAYDIAX will conduct first-in-human applications of TACT to generate early clinical evidence. Second, the company will advance the system toward series maturity, ensuring it meets reliability, performance and regulatory expectations for broader clinical deployment.
Third, the financing supports the build-out of sales, production and quality structures, laying the groundwork for commercial installations once regulatory milestones are achieved. Entering the clinical phase marks a major value-creation step, forming the basis for approval processes and future scaling.
A new category in interventional oncology
RAYDIAX is developing TACT, a dedicated therapy-assistance CT system designed specifically for minimally invasive cancer treatments. Unlike conventional CT scanners, TACT integrates therapy planning, procedure guidance and treatment monitoring within a single platform tailored to interventional workflows.
The aim is to expand access to minimally invasive therapies at a time when ageing populations and rising cancer incidence are placing intense pressure on hospital systems. These procedures can reduce complications, shorten hospital stays and ease surgical bottlenecks, but they require precise imaging support.
With TACT, RAYDIAX intconcludes to establish a new product category in interventional oncology, enabling clinicians to deliver tarobtained therapies with greater confidence and efficiency.
A spin-off built on deep research roots
RAYDIAX, a German company founded in 2022 to develop a specialised, therapy-supporting CT system for minimally invasive cancer procedures, was founded by a team including CEO Dr. Thomas Hoffmann, Dr. Tim Pfeiffer, Andre Mewes, Robert Frysch, and Benjamin Fritsch. The company aims to enhance image-guided procedures.
The company emerged from years of research into minimally invasive, image-guided therapy technologies. The team combines expertise in computed tomography hardware, software development and clinical workflow optimisation, capabilities shaped within the stimulate research environment.
As RAYDIAX prepares TACT for its first clinical utilize, it stands at a pivotal moment: advancing a technology that could expand cancer-treatment capacity at scale, while supporting hospitals manage growing demographic and medical pressures. The next phase, real-world patient studies, will determine how soon this new category of therapy-assistance CT can launch transforming interventional oncology across Europe.
Dr. Thomas Hoffmann, CEO and Co-Founder of RAYDIAX: “With the successful closing of our Series A1, we have reached a decisive milestone on our path toward clinical application. Following the successful seed phase and the development of our preclinical prototype, we are now focapplying on generating early clinical evidence as part of the planned first-in-human studies. At the same time, we are establishing the organisational foundations for market entest. The continued trust of our existing investors, along with the support of new strategic partners, confirms the technological maturity and market potential of our approach.”
Steffen Schmidt, CFO of the GETEC Group: “As the GETEC Group, we are pleased to invest in innovative technologies at our locations. After investing in new technological approaches in the field of magnetic resonance imaging through Neoscan Solutions, we became aware of RAYDIAX in the CT sector. With its innovative technology, RAYDIAX enables focutilized live CT imaging that reduces radiation exposure for both patients and physicians, as well as procedure time in the operating room. In addition to increasing efficiency in medical processes, RAYDIAX has also created a larger CT gantest opening possible, which will enable new surgical methods in the future, such as the utilize of robotics. Altoobtainher, this convinced us.”
Klemens Gutmann, Founder of Regiocom and Business Angel: “As an engineer, I am particularly interested in complex technical systems. The strong scientific foundation and the outstanding technical expertise of the founding team convinced me. The TACT system fills a functional gap in operating room workflows – specifically in interventional radiology.”
Dr. Jan Alberti, Managing Partner at bmp Ventures: “With the successful closing of the Series A1, RAYDIAX reaches a decisive turning point from technology development to clinical application and market entest. TACT addresses a clearly defined clinical necessary in interventional oncology and has the potential to establish a new device category for minimally invasive cancer therapies. We see RAYDIAX as being exceptionally well positioned to establish an international presence in this growing market segment.”
Dr. Jan Engels, Senior Investment Manager at High-Tech Gründerfonds: “RAYDIAX is developing a technology with the potential to significantly improve the care of cancer patients. We are proud to see the strong progress the team has created since our seed investment – culminating in the recently closed Series A1 and the prestigious EIC Accelerator grant. Since the early stages, Thomas and his team have consistently taken the right steps toward achieving clinical relevance, and we view forward to continuing to support them closely on their journey.”
Leave a Reply